| abstract |
The disclosure provides methods for determining liver fibrosis development, risk and prognosis. The method includes measuring in a biological sample, one or more eicosanoids such as 5-HETE, 7,17-DHDPA, arachidonic acid, EPA, 16-HDOHE and 9-HODE using gas or liquid chromatography in combination with mass spectrometry. Methods of determining an improvement in hepatic collagen content are also described. |